Envoy Medical, Inc. (COCH) Key Metrics
COCH valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $51.6M
- Enterprise value
- $36.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 249.1
- Price / book
- 15.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.95
COCH key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCOCH valuation Price multiples at each fiscal year-end price.
COCH returns How much profit the business earns on the capital it uses.
COCH per-share figures Results divided by the shares outstanding at year-end.
COCH financial health Debt, liquidity and how easily interest is covered.
COCH efficiency & capital use Working capital cycle and where the cash goes.
COCH valuation history
COCH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
COCH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
COCH cash returned to shareholders
COCH price vs earnings per share
COCH key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $15.4M | $26.9M | — | — | — | — |
| Enterprise value | $12.6M | $41.0M | — | — | — | — |
| Price / sales | 63.8 | 119.4 | — | — | — | — |
| EV / sales | 52.1 | 182.4 | — | — | — | — |
| Earnings yield | −154.5% | −77.4% | — | — | — | — |
| Free cash flow yield | −119.5% | −70.4% | — | — | — | — |
| Dividend yield | 11.8% | 9.1% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 11.8% | 9.1% | — | — | — | — |
| Share price at fiscal year-end | $0.66 | $1.43 | $1.81 | $10.02 | $9.74 | — |
| Per share | ||||||
| Revenue per share | $0.01 | $0.01 | — | — | — | $0.00 |
| Earnings per share | −$1.02 | −$1.11 | — | — | — | −$0.00 |
| Operating cash flow per share | −$0.78 | −$0.96 | — | — | — | — |
| Free cash flow per share | −$0.79 | −$1.01 | — | — | — | — |
| Cash per share | $0.16 | $0.29 | — | — | — | $0.00 |
| Book value per share | −$0.51 | −$1.00 | — | — | — | $0.00 |
| Tangible book value per share | −$0.51 | −$1.00 | — | — | — | $0.00 |
| Dividends per share | $0.08 | $0.13 | — | — | — | — |
| Capex per share | $0.01 | $0.05 | — | — | — | — |
| Debt per share | $0.04 | $1.05 | — | — | — | — |
| Shares outstanding | 23.3M | 18.8M | — | — | — | 60.4M |
| Change in shares outstanding | +23.8% | — | — | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | — | — | — | — | — | −2.9% |
| Return on assets (ROA) | −236.4% | −210.0% | −552.7% | −614.8% | −632.3% | −0.6% |
| Return on tangible assets | −277.6% | −180.2% | −361.8% | −623.0% | −330.6% | −0.6% |
| Financial health | ||||||
| Total debt | $919,000 | $19.7M | $562,000 | $34.5M | $23.5M | — |
| Cash & short-term investments | $3.7M | $5.5M | $4.2M | $183,000 | $1.1M | $25,000 |
| Net debt | −$2.8M | $14.2M | −$3.7M | $34.4M | $22.4M | −$25,000 |
| Debt / assets | 0.11 | 1.70 | 0.07 | 13.51 | 8.95 | — |
| Current ratio | 0.54 | 1.24 | 1.02 | 0.65 | 1.76 | 0.26 |
| Quick ratio | 0.41 | 1.02 | 0.83 | 0.14 | 0.99 | 0.26 |
| Interest coverage | -14.0 | -23.6 | — | — | — | — |
| Working capital | −$5.3M | $1.8M | $171,000 | −$871,000 | $1.1M | −$70,693 |
| Invested capital | −$14.6M | −$4.7M | −$5.4M | −$1.8M | −$22.6M | −$701 |
| Tangible asset value | −$11.8M | −$18.8M | −$1.8M | −$36.2M | −$45.0M | $24,299 |
| Net current asset value | −$14.0M | −$21.0M | −$2.6M | −$37.1M | −$45.1M | −$70,693 |
| Graham net-net per share | −$0.68 | −$1.25 | — | — | — | −$0.00 |
| Capital allocation | ||||||
| Dividends paid | $1.8M | $2.4M | $0 | — | — | — |
| Share buybacks (net) | $0 | $0 | — | — | — | — |
| Capex / revenue | 74.3% | 435.6% | 48.4% | 92.0% | 40.3% | — |
| Capex / depreciation | 0.59 | 5.66 | 1.15 | 2.91 | 1.76 | — |
| Stock-based compensation / revenue | 36.5% | 249.8% | 498.4% | 0.0% | — | — |
| R&D / revenue | 5,180.9% | 4,524.0% | 2,834.2% | 2,099.2% | 1,270.6% | — |
| SG&A / revenue | 3,797.1% | 3,804.4% | 2,825.9% | 1,464.1% | 797.7% | — |
| Efficiency | ||||||
| Days sales outstanding | 645.2 | 720.3 | 64.1 | 99.3 | 103.6 | — |
| Days of inventory on hand | 679.5 | 765.4 | 624.3 | 863.0 | 503.1 | — |
| Days payables outstanding | 954.7 | 788.5 | 591.4 | 609.8 | 179.6 | — |
| Cash conversion cycle (days) | 370.0 | 697.1 | 97.0 | 352.6 | 427.2 | — |
| Receivables turnover | 0.57 | 0.51 | 5.69 | 3.67 | 3.52 | — |
| Payables turnover | 0.38 | 0.46 | 0.62 | 0.60 | 2.03 | — |
| Inventory turnover | 0.54 | 0.48 | 0.58 | 0.42 | 0.73 | — |
| Asset turnover | 0.02 | 0.02 | 0.06 | 0.09 | 0.23 | 0.00 |
| Average receivables | $426,000 | $444,000 | $55,500 | $64,500 | $88,000 | — |
| Average payables | $2.3M | $1.6M | $1.3M | $832,000 | $378,346 | $95,693 |
| Average inventory | $1.6M | $1.6M | $1.3M | $1.2M | $1.1M | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from COCH's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
COCH valuation and financial ratios
It ended the year with $0.9 million of debt and $3.7 million in cash and short-term investments, a net cash position of $2.8 million. It returned $1.8 million to shareholders: $1.8 million in dividends and $0 in share buybacks. The share count fell 61.5% from 60.4M to 23.3M over 5 years.
See the COCH income statement, the COCH chart for price history, or the COCH stock overview for the latest quote and news.
COCH key metrics FAQ
How much debt does Envoy Medical have?
Envoy Medical had total debt of $0.9 million at the end of fiscal 2025 and more cash than debt.
What is Envoy Medical's dividend yield?
Envoy Medical paid $1.8 million in dividends in fiscal 2025 ($0.08 per share), a payout ratio of —.
What is Envoy Medical's free cash flow yield?
Envoy Medical generated -$18.4 million of free cash flow in fiscal 2025, a free cash flow yield of −119.5% on its market value at year-end ($15.4 million).
What is Envoy Medical's current ratio?
Envoy Medical's current ratio was 0.54 at the end of fiscal 2025: current assets were 0.54 times current liabilities.